COVID 19 associated Rhino- Orbital- Cerebral Mucormycosis: A proposed Classification and Treatment Strategies.
Infect Disord Drug Targets 2022:IDDT-EPUB-122400. [PMID:
35400327 DOI:
10.2174/1871526522666220408110135]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 11/06/2021] [Accepted: 12/30/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE
Mucormycosis is a rare fungal disease and was known to affect only immunocompromised hosts, but in the COVID 19 pandemic, a surge in the cases of Rhino- Orbital-Cerebral Mucormycosis have been reported, and the cause still unknown. As the disease was a rare entity there was no classification considering the sprerad and proper management at various stages of spread.
METHOD
Extensive literature search with the terms " Mucormycosis", "Invasive Fungal Sinusitis" and "COVID 19 associated Mucormycosis", "Mucormycosis in COVID" was made on Pubmed, Scopus and Embase database, taking into consideration case histories revealing the site of involvement and treatment according to the extension of the disease.
RESULTS
Relevant articles were analysed and it was found that there is no specific classification of the disease entity and proper surgical and medical management guidelines to date and the disease spread followed a pattern related to the first site of involvement and few reports also suggested skip lesions.
CONCLUSION
This review is an attempt through which, we elaborate the pathophysiology of Mucormycosis and its spread and propose a classification which will be helpful in determining policies for control and prevent complications, morbidity, and mortality.
Collapse